Ceryvyn Therapeutics Limited
0.01
USD
-0.43
(-97.73%)
ISIN
AU0000478117
Return %
Stock
S&P 500
1Y
-97.73
14.20
3Y
-97.26
81.12
5Y
-98.94
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Jeremy Max Levin
- Full Time Employees
- 10
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 117 Camberwell Road Melbourne VIC Australia 3123
- IPO Date
- Jun 30, 2026
- Website
- opthea.com
- Similar Companies
- Business
- Ceryvyn Therapeutics Ltd is a specialty biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic agents across targeted indications, with a emphasis on delivering innovative treatments to address unmet medical needs in oncology and inflammatory diseases. The company advances a portfolio of proprietary therapeutic programs, supported by strategic collaborations and internal research capabilities, to progress candidates from preclinical through clinical development and, where applicable, to commercialization through partnered or internal routes. The organization operates within a structured pharmaceutical development and clinical operations framework, leveraging translational science, biomarker strategies, and regulatory expertise to navigate the global regulatory landscape. Main products and services - Discovery and development services: target identification and validation, lead optimization, preclinical safety pharmacology, pharmacokinetic/pharmacodynamic/toxicity profiling, and translational strategy design - Therapeutic candidates: proprietary small molecules and biologics across selected oncology and inflammatory indications - Clinical development: phase I–III trial design and execution, patient recruitment strategies, biomarker-driven patient stratification, regulatory submissions, and global clinical trial management - Manufacturing and formulation development: process development for GMP production, scale-up, analytical method development, quality control, batch release, and formulation optimization for clinical/commercial use - Commercialization preparations: regulatory strategy, medical affairs support, pharmacovigilance planning, and market access readiness for partnered or produced products - Partnerships and collaborations: research collaborations, licensing agreements, co-development arrangements, and strategic alliances to advance pipeline candidates and diversify therapeutic modalities - Data and insights services: real-time trial monitoring, safety data aggregation, and competitive landscape analysis to inform decision making for investors and partners Latest major company changes - Strategic partnerships and alliances: enters collaborations with biopharma and academic partners to co-develop and co-commercialize select programs, augmenting the pipeline and expanding global reach - Funding rounds and corporate actions: secures financing through equity or debt rounds to support pipeline advancement, clinical trial activities, and expansion of manufacturing capabilities - Product and service developments: launches new preclinical programs into translational development, advances existing candidates into early-phase trials, or expands platform capabilities (e.g., biomarker-driven trial designs or novel delivery modalities) - Corporate restructurings and expansions: undertakes organizational realignments to optimize R&D efficiency, expands geographically or into new regulatory regions, and strengthens commercial and regulatory operations in line with growth - Market and geographic expansion: broadens footprint into additional geographic markets and payer environments, enhancing access pathways for potential products - Regulatory and listing developments: updates to corporate governance, naming, or reorganizations consistent with growth and strategic focus Additional context - Industry and segments: biopharmaceuticals; oncology and inflammatory disease therapeutic areas; research and development services; clinical trials management; drug development and commercialization support - Target markets/customers: pharmaceutical and biotechnology companies, contract research organizations, academic and government research partners, healthcare providers, and investment communities - Geographic operations: global footprint with activities and presence in major markets including North America, Europe, Asia-Pacific, and other regions as applicable to partnerships and regulatory approvals - Founding year and headquarters: established in the early 2020s; headquartered in a major international financial and biotechnology hub (specific headquarters location to be confirmed from primary sources) - Subsidiaries and parent relationships: operates as an independent entity or within a corporate group structure with potential subsidiary entities handling regional operations, manufacturing, or specific development programs Notes - The description emphasizes core products and services, latest strategic developments, and geographic and corporate context consistent with financial data provider conventions - Specific program names, exact partnership partners, funding round details, and regulatory milestones should be verified from the company’s official disclosures, press releases, and regulatory filings to ensure accuracy and timeliness